FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Szekeres David Leslie
2. Date of Event Requiring Statement (MM/DD/YYYY)
10/13/2020 

3. Issuer Name and Ticker or Trading Symbol

HERON THERAPEUTICS, INC. /DE/ [HRTX]
(Last)        (First)        (Middle)

4242 CAMPUS POINT COURT, SUITE 200
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
EVP, Chief Operating Officer /
(Street)

SAN DIEGO, CA 92121      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 3571 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)  (1)3/17/2026 Common Stock 170000 $16.20 D  
Employee Stock Option (Right to Buy)  (1)10/7/2026 Common Stock 50000 $16.83 D  
Employee Stock Option (Right to Buy)  (2)12/21/2026 Common Stock 79167 $13.00 D  
Employee Stock Option (Right to Buy)  (2)12/18/2027 Common Stock 90000 $17.00 D  
Employee Stock Option (Right to Buy)  (2)12/15/2028 Common Stock 92000 $24.97 D  
Employee Stock Option (Right to Buy)  (2)12/19/2029 Common Stock 115000 $25.02 D  
Employee Stock Option (Right to Buy)  (2)10/13/2030 Common Stock 156000 $15.72 D  
Restricted Stock Units  (3) (3)Common Stock 20000 $0.00 D  

Explanation of Responses:
(1) The stock option is fully vested and exercisable.
(2) The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant.
(3) The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Szekeres David Leslie
4242 CAMPUS POINT COURT
SUITE 200
SAN DIEGO, CA 92121


EVP, Chief Operating Officer

Signatures
/s/ Lisa Peraza Attorney-in-fact for David Szekeres10/20/2020
**Signature of Reporting PersonDate

Heron Therapeautics (NASDAQ:HRTX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Heron Therapeautics Charts.
Heron Therapeautics (NASDAQ:HRTX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Heron Therapeautics Charts.